Corpus ID: 2823627

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

@article{Janmaat2003ResponseTE,
  title={Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.},
  author={Maarten L. Janmaat and Frank A. E. Kruyt and Jose A. Rodriguez and Giuseppe Giaccone},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 6},
  pages={
          2316-26
        }
}
  • M. Janmaat, F. Kruyt, +1 author G. Giaccone
  • Published 1 June 2003
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In this study, we examined the molecular mechanisms that underlie the antitumor effects of the anti-EGFR monoclonal antibody C225 (Cetuximab) and the selective EGFR tyrosine kinase inhibitor ZD1839 (Iressa; AstraZeneca) in non-small cell lung cancer (NSCLC) cell lines. Cell growth, assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, was inhibited at low concentrations… Expand
Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer
TLDR
The results suggest that VJ inhibited cancer cell growth and could be a potent molecule to inhibit EGFR and AKT signaling in NSCLC. Expand
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
TLDR
Preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefITinib and may offer a novel therapeutic strategy for the treatment of NSCLC. Expand
Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
TLDR
Investigation of the combined inhibitory effect of the mTOR inhibitor RAD001 and the EGFR-TKI gefitinib in three EGFR wild-type NSCLC cell lines indicates that the dual inhibition of the EGfr/mTOR pathways may be a promising approach to treat EGFRWild-typeNSCLC; however, this may be dependent on the PIK3CA mutation status. Expand
Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines
TLDR
The data show that TGF-alpha expression identifies a subset of human pancreatic cancer cells that is dependent on EGFR signaling in vitro and in vivo and may represent an effective means of identifying EGFR-responsive primary tumors. Expand
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
TLDR
An in vitro model of acquired resistance to EGFR tyrosine kinase inhibitors is developed and bortezomib treatment is suggested to be a useful approach to overcome resistance to anti-EGFR therapies. Expand
Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
TLDR
EGFR inhibitors can provide partial regulation of cisplatin-mediated apoptosis in OSCC cells by modulating expression of cIAP-1, XIAP, Bcl-2, B cl-xL, Bax and Bak, and EGFR inhibitors down-regulated expression levels of the anti-apoptotic proteins, whereas those of the pro-ap optotic proteins Baxand Bak were up-regulated, and neither cI AP-2 nor survivin were affected. Expand
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
TLDR
Gefitinib was statistically significantly more effective than cetuximab at inhibiting growth of EGFR mutant cells and apoptosis in NSCLC cells, and EGFR mutations in NSClC cells are associated with sensitivity to gefit inib but not to cetUXimab. Expand
Pancreatic Cancer Cell Lines Activation and Sensitivity to Gefitinib ( Iressa ) in Human Constitutive Epidermal Growth Factor Receptor Pathway Expression Drives α Transforming Growth Factor Updated
The epidermal growth factor receptor (EGFR) is considered an important therapeutic target in pancreatic cancer, but it is currently impossible to identify those patients who are most likely toExpand
Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
TLDR
The results suggest that the EGFR signaling pathway may, in part, regulate Fas-mediated apoptosis in OSCC cells through c-FLIP expression. Expand
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
TLDR
Gefitinib treatment decreased EGFR, ERK1/2, and Akt phosphorylation in EGFR mutant cell lines whereas cetuximab had relatively little effect, and EGFR mutations in NSCLC cells are associated with sensitivity to gefit inib but not to cetUXimab. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
TLDR
The antitumor effect of this EGFR-selective tyrosine kinase inhibitor ZD-1839 is demonstrated and a rationale for its clinical evaluation in combination with cytotoxic drugs is provided. Expand
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
TLDR
Akt/PKB is identified as a constitutively active kinase that promotes survival of NSCLC cells and modulation of Akt/P KB activity by pharmacological or genetic approaches alters the cellular responsiveness to therapeutic modalities typically used to treat patients withNSCLC. Expand
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression
TLDR
Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis, and ZD1839, at the doses studied, is a potent inhibitor of proliferation. Expand
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
  • F. Ciardiello, R. Caputo, +6 authors G. Tortora
  • Medicine, Biology
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
It is demonstrated that the antitumor effect of ZD1839 is accompanied by inhibition in the production of autocrine and paracrine growth factors that sustain autonomous local growth and facilitate angiogenesis, and that this effect can be potentiated by the combined treatment with certain cytotoxic drugs, such as paclitaxel. Expand
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
TLDR
The association between overexpression of EGFR, TGF-alpha, or both, and overall survival of patients with resectable NSCLC, and findings suggest that this growth factor/receptor loop is more important for lung tumor formation than for tumor progression. Expand
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
TLDR
Activity was unaffected by p53 status, but was reduced in cells strongly dependent on epidermal growth factor receptor signalling in the presence of an intrinsically activated mitogen-activated protein kinase pathway. Expand
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
TLDR
Examination of C225 effects on radiation response in SCCs demonstrates enhancement in radiosensitivity and amplification of radiation-induced apoptosis, and C225 represents a promising growth-inhibitory agent that can influence cellular proliferation, apoptosis and radiosensitivity in S CCs of the head and neck. Expand
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
TLDR
C Cotreatment with C225, an anti-EGF receptor-blocking monoclonal antibody, further enhanced the antitumor activity of PD153035, suggesting mechanisms of action for C225 other than competition with ligand binding. Expand
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
TLDR
Therapeutic disruption of EGFR or ErbB2/neu protein function in vivo may result in partial suppression of angiogenesis, a feature that could enhance the therapeutic index of such agents in vivo and endow them with anti-tumor effects, the magnitude of which may be out of proportion with their observed cytostatic effects in monolayer tissue culture. Expand
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
TLDR
It is suggested that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family tyrosine kinase signaling and novel strategies to treat these particularly aggressive tumors are suggested. Expand
...
1
2
3
4
5
...